In news sure to excite even the most melancholy of artificial intelligence-powered chatbots, mental health platform Woebot has closed its series B funding round with a whopping $90 million.

Though tech giants Microsoft, Amazon and Google typically vie against one another to become a collaborator’s sole cloud provider, they’ll be working in harmony for once to support the National Institutes of Health’s biomedical research work.

IM Therapeutics said its lead, and only, clinical-stage candidate exhibited positive safety, tolerability, pharmacokinetics and mechanism of action in a phase 1b clinical trial.

As Lexeo Therapeutics ushers two gene therapies toward the clinic, the company is adding another three heart disease programs to its already busy pipeline. The assets come through Lexeo’s acquisition of Stelios Therapeutics, which was founded on research out of the University of California, San Diego.

The neurostimulation company Nevro has secured a new FDA approval for its chronic pain treatment device, aimed at patients suffering from nerve damage associated with diabetes.

After a tumultuous year for its MAGEC line of spinal curve-correcting magnetic rod systems, NuVasive has resumed shipping of the latest version of the system, even as the company works with the FDA to continue investigating safety issues associated with the device.

It will be a little while before Merck finds out how well its long-acting HIV drug prevents infection, but in the meantime, the company is revealing phase 2 data—and they’re promising.

The gene HTRA1 produces a protein that has been linked with age-related macular degeneration (AMD), a leading cause of blindness in older people. The protein naturally increases with age and has long been thought to contribute to AMD and other diseases of aging, including arthritis.

Viz.ai has already brought its FDA-cleared artificial intelligence-powered clinical triage software to stroke care, helping healthcare providers quickly detect and begin treating intracranial hemorrhage and large vessel occlusion. Now, it’s expanding throughout the body, adding tools to triage cases of pulmonary embolism and aortic dissection to the Viz intelligent care coordination platform.

Polyphor is closing its failed phase 3 breast cancer clinical trial and planning to lay off staff to lower its costs. The Swiss biotech said its “initial” restructuring will affect 29 positions and it is continuing a strategic assessment.